Asahi Life Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Asahi Life Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6,591	Closed	-$357K	–	165
2025 Q3	$357K	Buy	6,591 +1,071	+19%	+$61.3K	0.2%	135
2025 Q2	$303K	Buy	5,520 +140	+3%	+$8.24K	0.18%	144
2025 Q1	$380K	Buy	+5,380	New	+$362K	0.25%	104
2024 Q4	–	Sell	-5,470	Closed	-$384K	–	172
2024 Q3	$384K	Buy	+5,470	New	+$457K	0.23%	113
2023 Q4	–	Sell	-3,500	Closed	-$310K	–	168
2023 Q3	$310K	Buy	3,500 +40	+1%	+$3.56K	0.11%	115
2023 Q2	$300K	Buy	+3,460	New	+$326K	0.1%	144
2021 Q4	–	Sell	-4,870	Closed	-$376K	–	196
2021 Q3	$376K	Buy	4,870 +20	+0.4%	+$1.58K	0.05%	117
2021 Q2	$405K	Buy	4,850 +900	+23%	+$71.3K	0.05%	112
2021 Q1	$298K	Buy	+3,950	New	+$323K	0.04%	176

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Asahi Life Asset Management's BMRN Position: Q4 2025 in Review

Asahi Life Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 6,591 shares — an estimated $357K sold.

Asahi Life Asset Management first reported a position in BMRN in Q1 2021 and held it in 9 quarters. The position peaked at $405K in Q2 2021. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Asahi Life Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Asahi Life Asset Management sold 6,591 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $357K.
Asahi Life Asset Management first reported a position in BioMarin Pharmaceuticals in Q1 2021 and held it in 9 quarters.
Asahi Life Asset Management's BioMarin Pharmaceuticals position peaked at $405K in Q2 2021.
540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Asahi Life Asset Management's 13F filing for Q4 2025, filed 4 Feb 2026.